Author: admin

Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics

The Key Duchenne Muscular Dystrophy Companies in the market include – Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others.

 

The Duchenne Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

 

DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Forecast

 

Some of the key facts of the Duchenne Muscular Dystrophy Market Report:

  • The Duchenne Muscular Dystrophy market size was valued ~USD 2,150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In July 2025, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leading company in precision genetic medicine for rare diseases, released a statement noting that the U.S. Food and Drug Administration (FDA) informally requested the company to voluntarily pause shipments of ELEVIDYS (delandistrogene moxeparvovec), its gene therapy for Duchenne muscular dystrophy, within the U.S. Sarepta stated that it became aware of this potential request earlier in the day through media coverage, at the same time as the general public and patient communities.

  • In May 2025, Satellos Bioscience’s investigational therapy SAT-3247 was found to be safe, well-tolerated, and showed early indications of improved muscle strength in five adults with Duchenne muscular dystrophy (DMD). In the initial part of the Phase 1 trial (NCT06565208), the oral small molecule, administered alongside steroids, demonstrated a favorable safety profile in healthy participants. Additionally, the drug’s pharmacokinetics—how it is absorbed, distributed, metabolized, and excreted—performed as anticipated in individuals with DMD.

  • In March 2025, REGENXBIO’s investigational gene therapy, RGX-202—an adeno-associated virus (AAV) vector-based treatment for Duchenne muscular dystrophy (DMD)—continues to show promising results. Data from two additional patients in the Phase 1/2 AFFINITY DUCHENNE trial (NCT05693142) reveal that the therapy consistently generates strong levels of microdystrophin expression.

  • In February 2025, Solid Biosciences reported that its gene therapy candidate, SGT-003, for Duchenne muscular dystrophy (DMD) achieved 110% microdystrophin expression in early clinical testing. The announcement of 90-day biopsy results from the Phase I/II Inspire DMD trial (NCT06138639) led to a sharp surge in the company’s stock, which rose by 78.66%—jumping from $4.03 on February 14 to $7.20 at market open on February 18. Among the first three of six enrolled patients, the observed gene expression suggests a promising potential to slow disease progression and support muscle function.

  • In November 2024, Genethon, a leading gene therapy research organization established by AFM-Téléthon, shared encouraging data from the dose-escalation portion of its international Phase 1/2/3 clinical trial evaluating GNT0004, its gene therapy candidate for Duchenne muscular dystrophy (DMD). The results were presented at the ASGCT Breakthroughs in Muscular Dystrophy conference held November 19–20, 2024, in Chicago, IL. Following these positive findings, Genethon plans to initiate pivotal trials in Europe in the second quarter of 2025, with a U.S. launch expected to follow.

  • In September 2024, Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company dedicated to developing transformative treatments for genetically driven muscle diseases, has announced new clinical findings from its ongoing Phase 1/2 DELIVER trial. The study evaluates DYNE-251 in Duchenne muscular dystrophy (DMD) patients eligible for exon 51 skipping. Results revealed remarkable dystrophin expression and functional improvements across multiple patient cohorts.

  • In January 2024, ELEVIDYS (delandistrogene moxeparvovec) is a one-time gene therapy designed for ambulatory children aged 4 to 5 with Duchenne muscular dystrophy (DMD), a condition marked by progressive muscle weakening. This treatment targets patients with confirmed mutations in the dystrophin gene, essential for muscle function. ELEVIDYS works by delivering a gene that produces a shortened version of dystrophin, called ELEVIDYS micro-dystrophin, directly to muscle cells.

  • The United States holds the largest market share for Duchenne Muscular Dystrophy, valued at approximately USD 1.9 billion, surpassing the markets of the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

  • In January 2024, Santhera Pharmaceuticals initiated the availability of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) patients aged four years and older in Germany. This marks a significant milestone as Santhera Pharmaceuticals transitions into the “commercial stage” of its biopharmaceutical journey through the official launch of this medication in Germany.

  • In 2023, the United States reported approximately 17,000 total prevalent cases of Duchenne muscular dystrophy (DMM). The majority of cases were observed in children aged 5-9 years. It is anticipated that these numbers will increase by the year 2034.

  • In 2023, the United States had the highest number of prevalent cases of Duchenne muscular dystrophy (DMM) among the 7MM countries, totaling approximately 17,200 cases. This figure is projected to rise at a respectable compound annual growth rate (CAGR).

  • In the United States in 2023, there were approximately 13,800 cases of large mutation, around 3,400 cases of small mutation, and roughly 1,700 cases of point mutation. It is anticipated that as prevalence rates rise, these numbers will also increase during the study period from 2024 to 2034.

  • In the EU4 countries (Germany, France, Italy, and Spain) along with the United Kingdom, the highest prevalence of Duchenne Muscular Dystrophy (DMD) was observed in the UK, totaling approximately 3,000 cases in 2022. This was followed by Germany and France, whereas Spain had the lowest number of cases recorded in the same year.

  • In the present US market, there are several approved products—EMFLAZA (deflazacort), VYONDYS 53 (golodirsen), EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), and VILTEPSO (viltolarsen)—available for individuals with Duchenne Muscular Dystrophy (DMD). Within the EU4 countries and the UK, steroid therapies dominate the current market, accompanied by an approved medication designed for DMD patients with the nonsense mutation, TRANSLARNA (ataluren). However, in Japan, the sole approved treatment available is VILTEPSO (viltolarsen).

  • Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others

  • Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others

  • The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females

  • In 2023, the age group with the highest number of cases was 5-9, totaling approximately 5,700 cases, followed by the 10-14 age group with around 5,000 cases. Duchenne muscular dystrophy (DMD) is uncommon in individuals above the age of 30.

  • The Duchenne Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

 

Duchenne Muscular Dystrophy Overview

Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, typically becoming evident in early childhood between the ages of 3 and 5.

 

Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market

 

Duchenne Muscular Dystrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Duchenne Muscular Dystrophy Epidemiology Segmentation:

The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Duchenne Muscular Dystrophy

  • Prevalent Cases of Duchenne Muscular Dystrophy by severity

  • Gender-specific Prevalence of Duchenne Muscular Dystrophy

  • Diagnosed Cases of Episodic and Chronic Duchenne Muscular Dystrophy

 

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiology Forecast

 

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Duchenne Muscular Dystrophy Therapies and Key Companies

  • Givinostat (ITF2357): Italfarmaco

  • ATL1102: Antisense Therapeutics

  • SRP-9001: Sarepta Therapeutics

  • Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma

  • PF06939926: Pfizer

  • Pamrevlumab: FibroGen

  • CAP-1002: Capricor Therapeutics

  • Pamrevlumab: Fibrogen

  • Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics

  • EDG 5506: Edgewise Therapeutics

  • WVE N531: Wave Life Sciences Ltd

  • PGN EDO51: PepGen

  • UX810: Ultragenyx Pharmaceutical

 

Discover more about therapies set to grab major Duchenne Muscular Dystrophy market share @ Duchenne Muscular Dystrophy Treatment Landscape

 

Duchenne Muscular Dystrophy Market Strengths

  • The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development.

  • Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of VILTEPSO now.

 

Duchenne Muscular Dystrophy Market Opportunities

  • Wider commercial opportunity for therapies such as Capricor’s CAP-1002 and Antisense’s ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.

 

Scope of the Duchenne Muscular Dystrophy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others

  • Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others

  • Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies

  • Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Duchenne Muscular Dystrophy Unmet Needs, KOL’s views, Analyst’s views, Duchenne Muscular Dystrophy Market Access and Reimbursement

 

To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ Duchenne Muscular Dystrophy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Duchenne Muscular Dystrophy Market Report Introduction

2. Executive Summary for Duchenne Muscular Dystrophy

3. SWOT analysis of Duchenne Muscular Dystrophy

4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance

5. Duchenne Muscular Dystrophy Market Overview at a Glance

6. Duchenne Muscular Dystrophy Disease Background and Overview

7. Duchenne Muscular Dystrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Duchenne Muscular Dystrophy

9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices

10. Duchenne Muscular Dystrophy Unmet Needs

11. Duchenne Muscular Dystrophy Emerging Therapies

12. Duchenne Muscular Dystrophy Market Outlook

13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2020–2034)

14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies

15. Duchenne Muscular Dystrophy Market Drivers

16. Duchenne Muscular Dystrophy Market Barriers

17. Duchenne Muscular Dystrophy Appendix

18. Duchenne Muscular Dystrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics

Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight | VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski

The Key Pediatric Obesity Companies in the market include – Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharma, Jack Yanovski, and others.

 

DelveInsight’s “Pediatric Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pediatric Obesity, historical and forecasted epidemiology as well as the Pediatric Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Pediatric Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pediatric Obesity Market Forecast

 

Some of the key facts of the Pediatric Obesity Market Report:

  • The Pediatric Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, Novo Nordisk highlighted the effectiveness of its obesity treatment, Saxenda (liraglutide), in children under 12 through positive Phase III trial results. Participants receiving Saxenda experienced an average reduction of 5.8% in body mass index (BMI), whereas the placebo group saw a decrease of only 1.6%. The Phase III trial findings were presented at the European Association for the Study of Diabetes (EASD) conference in Spain.

  • In 2023, around 8 million children aged 5 to 19 were affected by obesity across the 7MM. With ongoing lifestyle trends, this figure is anticipated to rise substantially in the coming years.

  • Research indicates that the prevalence of overweight, including obesity, among children and adolescents aged 5–19 has surged from 8% in 1990 to 20% in 2022. This increase has been observed in both genders, with 19% of girls and 21% of boys classified as overweight in 2022.

  • Among the EU4 and the UK, Germany recorded the highest prevalence of childhood obesity cases, while Spain had the lowest.

  • Rhythm Pharmaceuticals intends to file a supplemental New Drug Application (sNDA) with the US FDA in Q2 2024 to extend IMCIVREE’s label to include children aged 2 to 6 years

  • Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharma, Jack Yanovski, and others

  • Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others

  • The Pediatric Obesity market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pediatric Obesity pipeline products will significantly revolutionize the Pediatric Obesity market dynamics.

 

Pediatric Obesity Overview

Pediatric obesity refers to the condition of having excess body fat in children and adolescents. It is a complex medical condition characterized by an abnormal or excessive accumulation of fat that may negatively affect a child’s health and well-being.

 

Get a Free sample for the Pediatric Obesity Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/pediatric-obesity-market

 

Pediatric Obesity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Pediatric Obesity Epidemiology Segmentation:

The Pediatric Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Pediatric Obesity

  • Prevalent Cases of Pediatric Obesity by severity

  • Gender-specific Prevalence of Pediatric Obesity

  • Diagnosed Cases of Episodic and Chronic Pediatric Obesity

 

Download the report to understand which factors are driving Pediatric Obesity epidemiology trends @ Pediatric Obesity Epidemiology Forecast

 

Pediatric Obesity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pediatric Obesity market or expected to get launched during the study period. The analysis covers Pediatric Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pediatric Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Pediatric Obesity Therapies and Key Companies

  • WEGOVY (semaglutide): Novo Nordisk

  • SAXENDA (liraglutide): Novo Nordisk

  • Tirzepatide: Eli Lilly and Company

  • VI-0521: VIVUS LLC

  • Sandostatin LAR: Novartis

  • Setmelanotide: Rhythm Pharmaceuticals

  • Orlistat: Jack Yanovski

 

Discover more about therapies set to grab major Pediatric Obesity market share @ Pediatric Obesity Treatment Landscape

 

Scope of the Pediatric Obesity Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski, and others

  • Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others

  • Pediatric Obesity Therapeutic Assessment: Pediatric Obesity current marketed and Pediatric Obesity emerging therapies

  • Pediatric Obesity Market Dynamics: Pediatric Obesity market drivers and Pediatric Obesity market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Pediatric Obesity Unmet Needs, KOL’s views, Analyst’s views, Pediatric Obesity Market Access and Reimbursement

 

To know more about Pediatric Obesity companies working in the treatment market, visit @ Pediatric Obesity Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Pediatric Obesity Market Report Introduction

2. Executive Summary for Pediatric Obesity

3. SWOT analysis of Pediatric Obesity

4. Pediatric Obesity Patient Share (%) Overview at a Glance

5. Pediatric Obesity Market Overview at a Glance

6. Pediatric Obesity Disease Background and Overview

7. Pediatric Obesity Epidemiology and Patient Population

8. Country-Specific Patient Population of Pediatric Obesity

9. Pediatric Obesity Current Treatment and Medical Practices

10. Pediatric Obesity Unmet Needs

11. Pediatric Obesity Emerging Therapies

12. Pediatric Obesity Market Outlook

13. Country-Wise Pediatric Obesity Market Analysis (2020–2034)

14. Pediatric Obesity Market Access and Reimbursement of Therapies

15. Pediatric Obesity Market Drivers

16. Pediatric Obesity Market Barriers

17. Pediatric Obesity Appendix

18. Pediatric Obesity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight | VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski

Samir Kahlot, 4X Founder, Reveals Lean Team Strategy Behind E-Commerce Growth

A Practical Mindset for Growing E-Commerce Brands While Staying Lean

NEW YORK – August 8, 2025 – Samir Kahlot, the renowned online marketer and founder, today announced his proven system for e-commerce companies to build lean, high-performing teams. This approach enables businesses to be agile, enabling brands to scale and reach key audiences.

“Too many e-commerce brands assume they need to keep hiring just because revenue is growing,” said Kahlot. “But you don’t need a big team to build a big company. In most cases, a small, dedicated group that grows with the business will outperform a bloated team.”

“A strong brand is built on a tight, agile team that’s aligned, committed, and trusted. You shouldn’t feel pressure to add headcount just to look ‘bigger’ from the outside,” added Kahlot.

He continued, “Instead of hiring someone new for every small task, focus on growing your internal team and giving them space to take initiative. Invest in training, offer room to grow, and create real incentives things that make people feel valued and want to stick around.”

“There’s no substitute for having people on your team who care about the brand as much as you do. Early on, I tried to do everything myself. I thought no one could do it better. But eventually I learned that if you want to scale, you have to let go and trust people who are better at specific things than you are. That’s what makes real growth possible.”

The takeaway from Kahlot is that people are a company’s greatest asset. A leaner and stronger team will outperform a large, fragmented one every time.

For more information, visit https://samirkahlot.com/

Media Contact
Company Name: Samir Kahlot
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://samirkahlot.com/

Easy Peasy Performance Training Is Redefining Strength for Girls – On and Off the Field

Easy Peasy Performance Training is launching with a bold mission: to shape strong, confident female athletes—not just on the field, but in life. This isn’t just a workout plan. It’s a lifestyle, a community, and a growing movement built around the idea that true athletic development comes from within.

At the heart of Easy Peasy is a belief that physical strength is only part of the equation. The program is designed to empower girls to rise to challenges, believe in themselves, and use their strength far beyond sport. Through science-backed strength and conditioning paired with a fun, supportive environment, girls are trained to show up with purpose—and play with confidence.

But Easy Peasy goes beyond training. The Squeeze, its signature podcast, features real conversations with inspiring women in sports—from professional athletes to coaches and wellness experts—offering girls meaningful insight and encouragement. Meanwhile, The Lemonade Stand, a digital content hub created by girls, for girls, is full of motivational interviews, fitness challenges, and feel-good fun. It’s a space where young athletes can build connection, celebrate strength, and stay inspired.

Leadership and service are also key pillars of the program. Easy Peasy encourages girls to give back through local events, donation drives, and acts of kindness—teaching them how to use their strength to uplift others and lead with purpose.

Whether she’s stepping onto the field, into the gym, or into a leadership role, Easy Peasy is built to make that moment feel exciting, earned, and joy-filled. Because this company isn’t just focused on building better athletes—it’s committed to building better humans.

To learn more or join the movement, visit www.easypeasypt.com or follow along on Instagram @easypeasypt.

Media Contact
Company Name: Easy Peasy Performance Training
Contact Person: Coach Sam & Coach Danielle
Email: Send Email
Country: United States
Website: www.easypeasypt.com

U.S. Drone Stocks Ready for Liftoff with Groundbreaking FAA Proposal (ZENA, AVAV, KTOS, ONDS)

The race to dominate the drone economy has just entered a new phase. On August 6, 2025, U.S. Transportation Secretary Sean P. Duffy unveiled a sweeping proposal that could dramatically expand where and how drones operate in American skies. The new Beyond Visual Line of Sight (BVLOS) rule aims to remove one of the biggest regulatory barriers in the industry. By allowing unmanned aircraft to fly without needing direct line of sight from the ground, this rule opens the door to broader commercial use across sectors like agriculture, shipping, infrastructure, emergency response, and energy.

Until now, companies had to seek individual waivers for BVLOS flights, limiting scale and discouraging investment. This proposal changes the game entirely. It gives American drone makers and service providers a clear runway for growth while enabling new business models to emerge. From autonomous crop monitoring to rapid medical delivery, the applications are vast, and the market opportunity is growing fast. The White House has made it clear this is a strategic move to give U.S. firms an edge over foreign competitors.

With a more supportive regulatory environment taking shape and commercial adoption set to accelerate, investors have a rare chance to get ahead of a major turning point in the drone market.

Now, let’s look at four stocks worth watching.

ZenaTech (Nasdaq: ZENA) is emerging as one of the most compelling names in the drone industry, blending high-performance unmanned aerial systems with a rapidly expanding enterprise software and Drone as a Service (DaaS) platform. As the FAA moves forward with a national framework for beyond visual line of sight (BVLOS) drone operations, ZenaTech’s vertically integrated model puts it in prime position to scale both domestically and abroad.

The company’s flagship drones are designed for fully autonomous operation, making them well-suited for the new BVLOS regime. ZenaTech has already logged tens of thousands of autonomous flight hours and operates in a range of critical industries, including precision agriculture, energy, infrastructure inspection, and defense. Through recent DaaS-focused acquisitions, ZenaTech now owns a national deployment footprint and a pipeline of recurring revenue contracts that reduce its reliance on hardware sales alone.

While many drone companies are focused solely on airframes or navigation, ZenaTech is building a complete ecosystem. Its CommandOS software platform combines AI-driven mission planning, real-time telemetry, edge analytics, and data lifecycle management—a key differentiator as large enterprise and government clients increasingly seek end-to-end drone solutions. With the infrastructure already in place to support remote autonomous operations, ZenaTech is poised to scale services rapidly as BVLOS flights become standard.

Strategic alignment with U.S. government priorities has also been a tailwind. ZenaTech is among a small number of American drone manufacturers that meet federal sourcing and cybersecurity requirements, a critical edge as federal agencies, defense contractors, and utility operators look to de-risk their supply chains. In July, the company was awarded a multi-year Department of the Interior contract covering autonomous drone services across five regions, and it is currently bidding on additional federal and state-level BVLOS initiatives. The company has also deepened its partnerships with agriculture technology leaders and electric utilities, two sectors likely to benefit early from BVLOS deregulation.

Financially, ZenaTech is in scale-up mode. In its most recent quarter, the company reported 60% year-over-year revenue growth and a 40% increase in software and services bookings. Gross margins are trending upward thanks to increased software adoption and higher utilization of its DaaS assets. While the company is not yet profitable, management has guided for positive adjusted EBITDA by mid-2026, driven by multi-year enterprise contracts and broader adoption of autonomous drone infrastructure.

With proven technology, strong government alignment, and an expanding recurring revenue base, ZenaTech is uniquely positioned to capitalize on the next phase of U.S. drone adoption. If the BVLOS rule accelerates industry-wide commercial deployments as expected, ZENA could be among the clearest beneficiaries—not just selling drones, but powering the operational backbone of a new autonomous aerial economy.

Ondas Holdings Inc. (Nasdaq: ONDS) appears especially well-positioned to benefit from the new BVLOS rule thanks to its fully autonomous drone platforms and recent momentum in the defense and public safety markets. Through its Ondas Autonomous Systems division—which includes American Robotics and Airobotics—the company offers advanced, AI-powered solutions like the Optimus System and Iron Drone Raider. Both platforms are designed for automated, remote operations and have already secured major regulatory milestones, including the first FAA Type Certification for automated BVLOS flights without an on-site operator.

Recent contract wins underscore the growing demand for Ondas’ drone technology. In June, the company announced a $14.3 million order from a leading defense customer for the Optimus System—its largest to date—and has since added new government contracts across the U.S., Europe, and the Middle East. Ondas also continues to expand its ecosystem with the Kestrel system, a counter-UAS and airspace management platform that enhances situational awareness and is deployable in both fixed and mobile settings.

Backed by strong financials, Ondas reported $4.2 million in Q1 revenue—up over 500% year-over-year—and reaffirmed its full-year revenue target of at least $25 million, with the majority expected to come from its drone business. The company ended the quarter with over $25 million in cash and is scaling production to meet rising demand.

With key FAA approvals already in place, a growing global customer base, and strategic partnerships with firms like Palantir and Volatus Aerospace, Ondas is not just ready for a BVLOS-enabled future—it’s already operating in one. Investors looking for a U.S.-based pure-play on autonomous drone infrastructure may find ONDS a compelling long-term opportunity.

AeroVironment, Inc. (Nasdaq: AVAV) is a well-established leader in defense technology, providing integrated autonomous systems and precision strike capabilities across air, land, sea, space, and cyber domains. The company’s portfolio spans uncrewed systems, counter-drone technologies, space-based platforms, directed energy, and electronic warfare solutions. With a national manufacturing presence and a strong innovation pipeline, AeroVironment delivers proven and future-focused technologies tailored to meet evolving military and government needs.

The company reported a strong finish to fiscal 2025, posting record fourth-quarter revenue of $275.1 million, a 40 percent increase year-over-year, and annual revenue of $820.6 million, up 14 percent. Net income for the quarter reached $16.7 million, while non-GAAP adjusted EBITDA hit a record $61.6 million. Total bookings for the fiscal year topped $1.2 billion, reflecting rising demand for AeroVironment’s products and services.

CEO Wahid Nawabi highlighted the company’s multi-generational Uncrewed Systems and Loitering Munitions as key growth drivers. He also emphasized the strategic acquisition of BlueHalo, which expanded AeroVironment’s portfolio with complementary technologies and enhanced domestic manufacturing capabilities. This combination positions the company well to meet increased global demand and deliver strong growth in fiscal 2026.

AeroVironment’s advanced Wildcat uncrewed aircraft system recently reached important milestones in DARPA’s Early VTOL Aircraft Demonstration. Designed for maritime operations, Wildcat has successfully completed key flight transitions and payload integrations, demonstrating its readiness for complex missions. This progress underscores AeroVironment’s commitment to innovation and operational excellence in next-generation air dominance.

The company’s current capital raise aims to support debt repayment and expand manufacturing capacity, fueling continued growth and execution. With a solid financial footing, expanding backlog, and cutting-edge technology, AeroVironment remains a key player in the evolving defense technology landscape.

Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS) is a technology-driven company focused on defense, national security, and commercial markets. The company is known for its internally funded research and development that rapidly brings affordable, mission-critical solutions to market. Kratos emphasizes proven technology over untested innovation, allowing it to deliver reliable, cost-effective products designed for rapid, large-scale manufacturing. This approach creates a competitive advantage, especially for large prime contractors and government clients.

Kratos specializes in a broad range of areas, including virtualized ground systems for satellites, command and control software, jet-powered unmanned aerial drones, hypersonic vehicles, propulsion systems for drones and missiles, and advanced microwave electronics for missile defense and counter-drone systems. The company also develops virtual and augmented reality training systems for warfighters.

In April 2025, Kratos received a sole-source production award worth approximately $30 million to manufacture air defense system hardware at its secure facilities. CEO Eric DeMarco highlighted Kratos’ reputation for delivering military-grade hardware that must perform flawlessly for national security customers. The company is already in large-scale production on multiple programs related to hypersonics, missile defense, and air defense systems.

Kratos is also expanding its automated truck platooning technology, deploying systems along major freight corridors in Ohio and Indiana in partnership with state agencies and the U.S. Department of Transportation. This technology, originally developed for military use, aims to improve safety, resilience, and efficiency across commercial logistics and critical infrastructure sectors.

Financially, Kratos reported first-quarter 2025 revenues of $302.6 million, reflecting solid organic growth and a strong backlog of $1.5 billion. The company maintains a healthy book-to-bill ratio and a robust pipeline of nearly $12.6 billion in bids and proposals.

Partnerships like the teaming agreement with GE Aerospace are advancing the development of affordable propulsion systems for next-generation unmanned aerial systems and combat aircraft. Kratos’ focus on cost-effective, scalable technologies positions it well to benefit from expanding defense budgets and evolving drone regulations.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ZenaTech Ltd. to assist in the production and distribution of content related to ZENA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: U.S. Drone Stocks Ready for Liftoff with Groundbreaking FAA Proposal (ZENA, AVAV, KTOS, ONDS)

iSpecimen: The $1.35 Biotech Behind a $200M Growth Strategy ($ISPC)

Sometimes, the market gets it wrong. And when it does—when there’s a glaring disconnect between price and reality—savvy investors don’t just notice. They act.

That’s exactly the setup unfolding with iSpecimen Inc. (NASDAQ: ISPC) right now.

Yesterday, the stock closed the regular session at $1.80, only to dip to around $1.35 after-hours. At first glance, it might look like weakness. But take a closer look—and more importantly, consider the timing.

The company’s most significant announcement to date—a plan to establish a $200 million digital treasury—was released after the market closed. That means the vast majority of investors didn’t see it. Retail traders missed it. Institutions missed it. And the after-hours move likely had nothing to do with the substance of the news and everything to do with a simple truth: most people weren’t looking.

This is where dislocation happens—not from bad news, but from blind spots. And in that blind spot lies opportunity.

Tiny Float Exposes Disconnect

With just 3.98 million shares outstanding, iSpecimen’s market cap now sits around $5.5 million—a fraction of the capital it plans to deploy in this future-forward treasury strategy. That kind of math doesn’t just suggest upside—it screams it.

Why? Because the initiative is more than symbolic. It’s structural. iSpecimen plans to diversify its treasury across top-performing digital assets, starting with a foundation built on Solana—chosen for its unmatched speed, cost-efficiency, and institutional-grade security. This isn’t an experiment. It’s an intentional strategy to create liquidity, preserve capital, and position the company with a financial engine that scales as fast as its operational footprint.

Let’s break down why ISPC chose this specific digital path:

  • High Throughput & Scalability: Solana’s hybrid consensus model enables fast, low-latency transactions at a scale biotech and research use cases demand.

  • Low Transaction Costs: Designed for frequent, small-value transfers—ideal for future data-driven or decentralized applications in life sciences.

  • Developer-Friendly Infrastructure: Tools like Anchor and a vibrant developer base allow for custom applications that enhance traceability, auditability, and integration.

  • Enterprise-Level Security: Solana’s virtual machine architecture brings security, performance, and trust to every transaction and smart contract execution.

This move is about more than managing capital—it’s about commanding it.

Financial Structure Meets Scientific Ambition

According to ISPC leadership, the move reflects a broader commitment to both financial and operational innovation. As adoption of next-generation financial tools accelerates, the company intends not just to participate—but to lead—with a well-structured, return-focused treasury strategy that aligns with its long-term growth vision.

That statement doesn’t come from a position of hope—it comes from execution. iSpecimen has already delivered a platform that simplifies and accelerates biospecimen sourcing for medical research. Now it’s applying that same forward-thinking rigor to how it capitalizes its future.

So why is the stock down after hours? Most likely because the market hasn’t caught up yet.

The press release hit after the bell. The dip in share price isn’t a rejection of the strategy—it’s evidence that most investors haven’t seen it yet. But they will. And when they do, the gap between ISPC’s $5 million market cap and its $200 million vision is unlikely to last. Especially with such a tight float.

This is how opportunity hides in plain sight. A sub-$2 biotech stock with operational revenue, an established footprint in the research space, and a roadmap that now includes one of the most innovative treasury strategies in the small-cap universe.

Investors looking for catalysts often chase news that’s already priced in. This one hasn’t even been priced at all. But that’s not likely to last.

No matter which way a stock moves during a typically low-volume and volatile after-hours session, fundamentals always get the final say. And once those fundamentals are fully accounted for—in this case, a $200 million digital warchest—those who acted during the disconnect won’t just be holding shares. They’ll be holding leverage. Because iSpecimen isn’t just preparing to participate in the future. It’s planning to fund it, power it, and lead it.

 

Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated five-thousand-dollars via wire transfer to create this content as part of a more extensive digital marketing program by IR Agency, Inc. Accordingly, this content may be reused and syndicated, with permission, beyond the channels used by Hawk Point Media, Llc. This disclaimer and the link to the broader disclosures must be part of all reproductions. That compensation creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in iSpecimen Inc. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: iSpecimen: The $1.35 Biotech Behind a $200M Growth Strategy ($ISPC)

Amid Global Grid Stress, Brenmiller Energy Emerges as a Trusted Ally for Energy Reliability ($BNRG)

The world isn’t short on ambition when it comes to energy. But right now—this summer—it’s being tested on something far more urgent: resilience.

From Phoenix to Paris, record-breaking heatwaves are pushing power grids to their limits. Utilities are scrambling to keep up with surging demand for air conditioning. Industry is being asked to throttle down. And for millions of people, the simple act of flipping on a light or cooling their home has become a question of whether the grid can hold.

That’s not a policy debate. That’s physics. And in moments like this, when energy reliability moves from the background to the forefront of public conversation, a new class of solutions begins to shine.

Brenmiller Energy (NASDAQ: BNRG) is one of them. This isn’t about solar versus gas, wind versus nuclear, or storage versus generation. Everyone in the energy sector—regardless of technology—deserves credit for getting us this far. The transition is real. The will is there. But these stress tests we’re seeing globally are a reminder that the journey doesn’t end with clean energy. It continues with reliable energy.

And that’s where thermal energy storage, especially at an industrial scale, proves its value—not someday, but today.

Proof-in-Practice, Not Theory

Brenmiller’s bGen™ platform doesn’t wait for the wind to blow or the sun to shine. It captures heat—any source, anytime—and stores it in crushed rocks. That heat can then be dispatched with precision when needed most, even in the middle of the night or during a midday grid crunch. And because the system is modular and flexible, it works just as well alongside renewables as it does with combined heat and power, industrial waste heat, or even future-facing integrations like small modular reactors.

This summer may feel like a turning point for public awareness, but for Brenmiller, it’s simply the latest proof point in a string of real-world deployments. A new version of BNRG’s bGen™ platform is being developed to serve Enel in Italy and multiple European manufacturing partners. And more significantly, Brenmiller has been selected to play a central role in two of the EU’s most ambitious clean heat initiatives: SolWinHy, an advanced €25 million solar-to-hydrogen project, and a €4 million Innovation Fund grant project to replace fossil fuels in district heating systems.

Each of these efforts moves thermal storage from concept to cornerstone.

And it’s not just funding that’s flowing—it’s commitments. These are public-private partnerships designed to scale. They represent Europe’s confidence in Brenmiller’s execution, and more broadly, in the role thermal energy must play to meet the continent’s decarbonization and grid reliability goals.

From Crisis Mode to Control

The headlines have made it impossible to ignore: heat domes, wildfires, rolling blackouts—climate volatility is no longer a distant warning. It’s here, and it’s straining the grid in real time.

But alongside the crisis, a different conversation is starting to take hold—one that moves past warnings and toward real solutions. Not hypotheticals or pilot programs, but technologies that are ready now. Precisely like Brenmiller’s bGen™.

Thermal energy storage may not make front-page news like hydrogen hubs or offshore wind, but its impact is just as critical. In fact, it’s one of the most immediate, effective tools to harden infrastructure against the very stressors we’re seeing this summer. It’s safe. It’s modular. It’s already working—and most importantly, it’s available when the grid needs it most.

That’s why this moment matters.

Because instead of more debates and delays, it’s time to focus on those who are delivering. And Brenmiller is doing exactly that.

 

Disclaimers and Disclosures:Hawk Point Media Group, LLC. (HPM) has not been compensated to produce and distribute this content. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities covered before or after any particular article, report and/or publication. HPM holds ZERO shares in Brenmiller Energy Ltd. Always do your own due diligence prior to investing in any publicly traded company. While HPM has not been compensated for creating and syndicating this content, HPM discloses having a prior services agreement with the company, and third parties, that expired in April 2025 and 2024, respectively. HPM is a digital marketing and consulting company. Therefore, it is possible that HPM will be retained in the future to create and syndicate digital content for Brenmiller Energy. Accordingly, while fact-based and sourced, our content may portray featured companies in only the most favorable way. A complete disclosure for all services provided and compensated for is linked below. Forward-Looking Statements: This article contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. The forward-looking statements contained or implied in this article are subject to other risks and uncertainties, many of which are beyond the control of the Company featured or HPM. Hawk Point Media Group, Llc. undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. For Hawk Point Media Group Llc’s full disclaimer and disclosure statement, click HERE.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Amid Global Grid Stress, Brenmiller Energy Emerges as a Trusted Ally for Energy Reliability ($BNRG)

RFT Introduces Subscription with Full Access to K-6 Teaching Materials

RFT Introduces Subscription with Full Access to K-6 Teaching Materials
An exciting new offering is set to transform how Australian primary educators access and use classroom resources all year round.

Sydney, NSW – August 7, 2025 – The trusted hub for Australian educators, Resources for Teaching (RFT), has launched a new subscription service that gives teachers unlimited access to its full catalogue of K-6 teaching resources. With over 380 digital resources developed specifically for the Australian Curriculum, this new offering is designed to support busy educators by simplifying lesson planning and enhancing student engagement in the classroom.

Teaching-Resources

The subscription is available at $119.88 AUD per year or $9.99 per month. It provides full access to all RFT’s downloadable content, including worksheets, task cards, activities, posters, and more for primary students. These kindergarten teacher resources span all major subject areas and year levels, offering everything from early childhood learning tools to advanced activities for upper primary students. Each resource is created with clarity, curriculum alignment, and classroom practicality in mind. New resources will also be added every month.

Educators can now explore a wide range of expertly written lesson plan for teachers, with built-in outcome links that help meet state and national curriculum requirements. For those working with younger learners, the kindergarten teacher resources section provides a variety of early literacy, numeracy, and developmental learning tools that are ready to use.

Teachers searching for engaging numeracy content will also appreciate the best math resources for teachers, which include printable and interactive activities suitable for daily instruction and revision. The platform is also home to some of the best teacher resources available online, offering reliable, classroom-tested content that teachers can implement with confidence.

“Teachers are under constant pressure to deliver engaging lessons while managing time constraints. This subscription was created to reduce that pressure by giving educators instant access to everything they need in one place. So, if you are looking for a complete lesson plan for English or quickly need to ready a worksheet, you can find it with us ready to go,” a spokesperson said.

Rosheen H, one of the first teachers who purchased the subscription said, “Love these resources!! They have made work super easy with pre-aligned work for the students. The students love these materials too as they have clear instructions and cute pictures.”

The RFT subscription also includes monthly email updates with the latest releases and full email support for members. As the platform continues to expand, educators across Australia can expect even more value and flexibility from their membership.

Teachers can sign up for the subscription by visiting RFT’s website and gain instant access to the resources.

About Company:

Resources for Teaching offers a wide range of worksheets, activities, task cards, lesson plans, and more downloaded content that align with the Australian curriculum. To know more, visit https://resourcesforteaching.com.au/.

Media Contact
Company Name: Resources for Teaching
Contact Person: Elise Simpson
Email: Send Email
Phone: 0426788853
Country: Australia
Website: https://resourcesforteaching.com.au/

Nappie Cakes Now Offers Hygienic Vacuum Sealed Nappy Cakes for Shipping

Nappie Cakes Now Offers Hygienic Vacuum Sealed Nappy Cakes for Shipping
A popular baby gift just got even better. Nappie Cakes is now using new ways to keep their products clean, fresh, and looking great when delivered.

Castle Hill, NSW – August 8, 2025 – Nappie Cakes, the recognised store for unique baby gifts, is setting a new benchmark in quality and care by vacuum sealing every nappy cake before shipping. This new feature keeps the nappies fresh, hygienic, and structurally intact during transport, so customers receive beautifully presented gifts that are ready to impress.

unique-baby-gifts

Each newborn nappy cake is crafted using a non-rolled method, which allows for more nappies in each cake and avoids any unwanted creases or contact.

“Our customers don’t want to unroll 30 individually handled nappies after their baby shower. That would be exhausting, especially for someone nearing the end of pregnancy. By leaving the nappies flat and untouched, we offer a more hygienic, thoughtful, and practical design,” says a spokesperson.

Once a design is complete, it is vacuum sealed in plastic to help the product hold its shape and protect it from external elements. These carefully packaged creations are ideal for those seeking baby hampers that go beyond the ordinary.

Nappie Cakes also offers convenient delivery options. Orders placed before 5 pm AEST are dispatched the next business day, with shipping available Australia-wide for just $20. Most orders are delivered within 1-2 business days. Deliveries to select Sydney Metro hospitals, such as Auburn Hospital, Westmead Hospital, Westmead Private Hospital, Norwest Private Hospital, and Blacktown Hospital, can be made directly to reception, as long as the recipient’s full name is provided.

For Sydney locals, the company offers free pickup from Baulkham Hills or Northmead, with parcels left safely at the front door. Local delivery is also available every Saturday between 8 am and 12 noon for just $10.

The company also personalises baby shower gifts based on their customers’ preferences. Each creation can be tailored to suit specific themes, colours, and budgets. The possibilities are endless.

“We’ve thought about the gifting experience from every angle. Freshness matters. So does presentation. Our vacuum sealing approach is part of our commitment to quality, practicality, and thoughtful gifting. You can be confident that the cake will look just as perfect when it arrives as it did when it left our hands,” said the spokesperson.

About Company:

Nappie Cakes is an Australian-based online store specialising in beautifully handcrafted nappy cakes and baby hampers. To know more, visit https://nappiecakes.com.au/

Media Contact
Company Name: Nappie Cakes
Contact Person: Minnie Lam
Email: Send Email
Phone: +61 41 441 2343
Address:18 Garthowen Cres
City: Castle Hill
State: NSW
Country: Australia
Website: https://nappiecakes.com.au/

BagelFresh Brings Fresh Flavors and Local Favorites to Robbinsville Township

BagelFresh Brings Fresh Flavors and Local Favorites to Robbinsville Township
BagelFresh has become a local staple, serving the Robbinsville community with a commitment to freshness, flavor, and variety. Known for its handcrafted bagels, hearty deli sandwiches, and sizzling grill options, BagelFresh has built a reputation as a go-to destination for breakfast, lunch, and everything in between.

With a passion for quality ingredients and made-to-order meals, BagelFresh offers an impressive selection of Bagels Robbinsville Twp that are boiled and baked daily on-site. Classic favorites like everything, sesame, and plain are joined by specialty options, all made to pair perfectly with a range of cream cheeses, spreads, and breakfast sandwich fillings.

For those seeking savory lunch choices, the Deli Robbinsville Twp menu is packed with fresh-cut meats, cheeses, and vegetables layered on bagels, wraps, or artisan breads. Signature sandwiches and custom builds alike are served with generous portions and bold flavors that cater to every palate.

Hot off the Grill Robbinsville Twp, customers can enjoy a variety of options including burgers, grilled chicken, Philly cheesesteaks, and more. Each item is crafted with care and cooked to order, making it a popular stop for those craving satisfying and freshly grilled meals.

Located conveniently in Robbinsville Township, BagelFresh continues to attract locals and newcomers with its friendly atmosphere, wide-ranging menu, and dedication to culinary excellence. Whether it’s a quick breakfast, a hearty lunch, or a family-friendly weekend brunch, BagelFresh delivers consistent quality in every bite.

For more information, visit the Robbinsville location and experience what makes BagelFresh a standout name in the local food scene.

Media Contact
Company Name: BAGELFRESH
Contact Person: Sikander Ranu
Email: Send Email
Phone: (609) 336-0022
Address:1320 US-130
City: Robbinsville Twp
State: NJ
Country: United States
Website: https://bagelfresh.com/